Abstract-Previous studies have shown beneficial effects of individual dietary approaches for blood pressure (BP) control, but their relative effectiveness is not well established. We performed a systematic review of published dietary pattern interventions and estimated the aggregate BP effects through meta-analysis. PubMed, EMBASE, and Web of Science databases were searched to identify studies published between January 1, 1990 and March 1, 2015. Studies meeting specific inclusion and exclusion criteria were selected. Data were pooled using random effects meta-analysis models. . Low-sodium; low-sodium, high-potassium; low-sodium, low-calorie; and low-calorie diets also led to significant systolic and diastolic BP reductions, whereas Mediterranean diet participants experienced a significant incremental reduction in diastolic but not systolic BP. Subgroup analysis also showed important variations in effectiveness based on duration, size, and participant demographics. In conclusion, dietary modifications are associated with clinically meaningful, though variable, reductions in BP. Some diets are more effective than others and under different circumstances, which has important implications from both clinical and public health perspectives. 
H ypertension, or high blood pressure (BP), is a major public health concern because it is the principal risk factor for cardiovascular disease and the leading contributor to worldwide mortality. 1, 2 In the United States, cardiovascular disease accounts for roughly $320 billion in annual combined direct and indirect healthcare costs. 3 Increased awareness, prevention, and treatment of hypertension could lead to significant cost savings within the healthcare sector. 3 Poor dietary habits, largely through their association with cardiovascular disease risk factors, are among the leading drivers of mortality and disability in the United States, accounting for 26% and 14%, respectively. 4 On the basis of evidence from clinical trials, meta-analyses, and systematic reviews, current clinical guidelines recommend lifestyle changes as the initial treatment for those with prehypertension and also as a complementary aspect of pharmacological therapy for all other stages. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Despite the positive findings from these individual studies, there remains some ambiguity among practitioners about what benefit is likely achievable from nonpharmacological interventions and which dietary approach to recommend. The aim of this meta-analysis was to quantify the aggregated BP-lowering effects associated with dietary interventions, as well as to compare the relative BP changes observed between specific dietary patterns.
Methods
The Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement was used to guide data extraction and reporting of results. 15 
Study Selection
We conducted a systematic and comprehensive review of the literature using PubMed (US National Library of Medicine), EMBASE (Elsevier B.V.), and Web of Science (Thomson Reuters) databases to identify relevant studies that were published in the past 25 years (after January 1, 1990) . Search terms included: hypertension and lifestyle or diet or low salt or low sodium or physical activity or exercise or weight loss in all fields and with associated Medical Subject Headings (MeSH terms). The search was limited to studies among humans and adults and only randomized controlled trials or controlled clinical trials were included. We identified additional titles by manually reviewing references from eligible articles, relevant systematic reviews and meta-analyses, and through discussions with clinical experts.
Two investigators (H.C.G. and S.G.R.) independently screened all titles and abstracts to determine eligibility for inclusion in the meta-analysis. In cases of discordance of opinion, a third author (M.K.A.) was consulted to achieve consensus. Studies published between January 1, 1990 and March 1, 2015 fulfilling all the following criteria were eligible for inclusion: (1) used a randomized, controlled trial design, (2) enrolled adult participants (aged ≥19 years); (3) tested an intervention that consisted of dietary pattern change(s); (4) had a comparison group receiving a control diet, advice only, or standard follow-up; (5) reported net change in systolic BP (SBP) and diastolic BP (DBP; or the information with which to calculate these data) and its associated variance, confidence intervals (CIs), or P value, and (6) had a duration of at least 6 months. Reasons for exclusion included: (1) trials conducted in populations with secondary hypertension, that is, chronic kidney disease, renovascular disease, or certain endocrine disorders; (2) trials conducted exclusively in patients with congestive heart failure (these patients are regularly prescribed medications that affect BP); (3) trials with overlapping participants; (4) trials of nutritional supplementation (such as fish oil or docosahexaenoic acid) as opposed to alteration of dietary pattern consumption; and (5) lack of a control group. There was no sample size requirement for inclusion or exclusion.)
Please review the online-only Data Supplement for a full review of the data extraction methods and dietary categorization criteria.
Statistical Analysis
Net BP effect during the duration of follow-up, between intervention and control groups, was calculated by subtracting the baseline (b) to follow-up (fu) change in the control group from the corresponding change in the intervention arm: (I fu −I b )−(C fu −C b ). Treatment effects for each trial were weighted by the inverse of the variance (standard error [SE] for the net effect). If not reported directly, SEs were derived from the CIs or P values of the net effect, or by calculation from the individual standard deviation (SD) or SE of effects within parallel groups (assuming a correlation of 0.5 between variances at baseline and follow-up, as described by Follmann et al). 16 The overall estimated mean net effect size of dietary modifications on BP was pooled across trials using a random effects model to account for the heterogeneity between studies with regard to the different dietary interventions and study designs, as well as participant ethnicity, age, sex, and health status. Heterogeneity was quantitatively assessed using Q and I 2 statistics. Several preplanned subgroup analyses were conducted. These a priori subanalyses involved examining net BP effect by: pre-existing hypertensive status, antihypertensive use, age (<50 versus ≥50 years), sex (<50% versus ≥50% male), pre-existing diabetes mellitus status, study duration (<12 versus 12-24 versus >24 months), sample size (<100 versus 100-1000 versus >1000 participants), body mass index (BMI) at baseline (<30 versus 30-35 versus >35 kg/m 2 ), presence or absence of physical activity recommendations, and whether BP reduction was considered the trial's primary outcome. The pooled effect size for subgroups was determined using a random effects model, and ANOVA was used to test for statistical differences between subgroups. In addition, meta-regression analyses were conducted to examine the impact of weight reduction (when reported) on net BP effect, as weight loss has been independently correlated with BP change. 12 Please review the online-only Data Supplement for a full review of bias assessment methods.
Comprehensive meta-analysis, version 3 (Biostat, Englewood, NJ), was used to perform meta-regression and subgroup analyses, and Review Manager, version 5 (The Cochrane Collaboration, Copenhagen, Denmark) was used for all other analyses.
Results

Study Selection and Characteristics
The initial search returned 3201 studies once duplicates were removed. Figure 1 shows the number of studies identified and excluded at various stages of the selection process. Ultimately, 24 individual trials were included in the analysis. From these trials, there were a total of 39 comparison groups (39 unique intervention groups and 27 control groups) with 23 858 total participants.
Characteristics of the 24 trials with their respective interventions and participants are detailed in Table S1 (online-only Data Supplement). Intervention arms varied in size from 11 to 2570 participants (median: 129). Trial duration ranged from 6 to 48 months of follow-up (median: 12 months). Twentyone of the 36 comparison groups that reported sex distribution were predominantly male. Ten trials were conducted in the United States, and 14 were based internationally. Race distribution was not consistently reported in trials conducted outside of the United States, whereas race was predominately white in US studies. Age ranged from 34 to 67 years (median: 45 years). There were 20 trials that reported hypertension status at baseline; among them, 14 comparisons exclusively included hypertensive patients, whereas another 11 comparisons included a mix of hypertensive and normotensive patients. Ten trials (14 comparison groups) included patients who were taking BP medication at baseline; in 4 of these, 100% of participants were receiving an antihypertensive medication. Mean BMI was in the overweight range (25-<30) in 22 comparison groups and the obese range (≥30) for all others (14 comparison groups). There were 3 comparison groups that exclusively included participants with diabetes mellitus and 14 comparisons composed of people without diabetes mellitus. Average baseline SBP and DBP ranged from 123.7 to 158.0 mm Hg (mean: 136.2 mm Hg) and 69.9 to 101.0 mm Hg (mean: 85.7 mm Hg), respectively.
Change in BP
Forrest plots for net SBP and DBP effect among all diets are presented in Figure 2 . Net SBP and DBP effect ranged from −12.10 to 7.00 mm Hg and −9.32 to 0.20 mm Hg, respectively. The overall pooled net effect of diet on SBP was −3.07 mm Hg (95% CI, −3.85 to −2.30) and for DBP was −1.81 mm Hg (95% CI, −2.24 to −1.38).
When trials were grouped by dietary patterns adopted ( Figure 3 . Low-sodium diets (6 comparison groups) led to a pooled net decrease in SBP and DBP of −2.06 mm Hg (95% CI, −3.50 to −0.63) and −1.30 mm Hg (95% CI, −2.37 to −0.23), respectively. Participants adopting combined lowsodium, high-potassium diets (5 comparison groups) experienced net SBP and DBP decreases of −3.14 mm Hg (95% CI, −6.27 to −0.02) and −2.01 mm Hg (95% CI, −3.40 to −0.62), respectively, whereas those adopting low-sodium, low-calorie diets (5 comparison groups) experienced net SBP and DBP decreases of −2.38 mm Hg (95% CI, −3.79 to −0.98) and −1.33 mm Hg (95% CI, −2.04 to −0.62). Among 13 comparison groups (11 trials) implementing low-calorie diets (some with low-fat components), the pooled net SBP effect was −3.18 mm Hg (95% CI, −4.24 to −2.11) and −1.28 mm Hg (95% CI, −1.87 to −0.69) for DBP.
Subgroup Analysis and Meta-Regression
Table summarizes the pooled net BP effects observed across different subgroups. All subgroups experienced statistically significant incremental BP reductions except: (1) people with diabetes mellitus, SBP (95% CI, −5.14 to 0.86); (2) baseline BMI >35, SBP (95% CI, −5.14 to 0.86); and (3) trials with >1000 participants, SBP (95% CI, −3.77 to 0.22). Larger net SBP (P=0.03) and DBP (P=0.02) reductions were noted among participants with pre-existing hypertension at baseline, compared with normotensives. Similarly, participants not already taking antihypertensive medications experienced significantly greater net SBP (P=0.01) and DBP (P=0.008) declines, compared with their counterparts already receiving pharmacological therapies. Groups with longer follow-up (>24 months) had a significantly smaller effect size (P<0.001 for both SBP and DBP) than those with medium (21-24 months) and short (<12 months) follow-ups. Smaller trials (n<100 participants) exhibited larger net effects (SBP [P<0.001] and DBP [P=0.001]) than medium (n=100-1000) and larger (n>1000) studies. There were significantly smaller net effects for both SBP (P=0.05) and DBP (P=0.04) in trials where the primary outcome was BP reduction. Net BP change was not significantly different across participants of different age, sex, diabetes mellitus status, baseline BMI, or in trials which also encouraged physical activity.
There were 30 comparison groups reporting net weight change (baseline to follow-up change in intervention minus the corresponding change in control), which ranged from −16.0 to +1.4 kg (mean: −4.56 kg). In meta-regression analysis ( Figure S2 ), there was a significant relationship noted between mean incremental weight loss in the intervention group and net BP effect for both SBP (P<0.001) and DBP (P=0.01). Specifically, for every additional 1 kg of weight loss experienced by intervention participants, there was an associated 0.36 mm Hg additional reduction in SBP (95% CI, 0.20-0.52) and 0.13 mm Hg additional reduction in DBP (95% CI, 0.03-0.24).
Please review the online-only Data Supplement for bias assessment results.
Discussion
This meta-analysis of 24 randomized controlled trials, covering studies during a 25-year period and including over 23 000 participants, showed that adopting healthful dietary modifications led to significant incremental reductions in both SBP and DBP versus control. These effects were generally consistent across different types of diets and among various population subgroups. Although the overall net effect was modest from an individual perspective, it is important to note that the control groups also experienced some benefit and the pooled results were incremental BP reductions experienced by those groups adopting dietary interventions. Furthermore, from a population standpoint, even relatively small reductions in BP can dramatically reduce the incidence of cardiovascular disease and mortality. 17 The range of effects also suggests that some patients may benefit to a greater degree than others. Our results have important clinical and public health implications, suggesting that dietary modifications are an effective method for controlling BP within the population and that certain approaches are better targeted to individuals with specific characteristics.
For all dietary interventions, compared with control groups, our study identified an incremental BP-lowering effect of −3.07 mm Hg and −1.81 mm Hg for SBP and DBP, respectively. Among the various diet subtypes, the DASH diet was associated with the greatest overall reduction in BP, with a net SBP effect of −7.62 mm Hg and a DBP effect of −4.22 mm Hg. Importantly, this magnitude is similar to trials examining single drug therapies in mild hypertension, suggesting the DASH dietary pattern may be an alternative to medication initiation in early stage hypertension. 6, 18 Significant, but smaller BP reductions were also evident among other dietary patterns. Furthermore, a recent meta-analysis found that vegetarian diets also led to lower SBP and DBP, though the trials included in that study were either too short for our analysis or conducted before 1990. 9 Interestingly, although participants adopting Mediterranean diets had significantly greater net DBP reductions, the effect on SBP was not statistically greater than that experienced among control groups. This is meaningful as a recent, major clinical trial showed that Mediterranean diets are associated with a lower incidence of 19 This finding, along with the results of our meta-analysis, suggest that there may be alternative cardiovascular advantages, beyond BP control, that contribute to the mortality benefit of the Mediterranean diet, as has been proposed in other studies. 20 Further research is needed in this area.
Subgroup analyses indicated that net BP reduction was not as great in trials of longer duration. Specifically, trials that lasted longer than 24 months had lower mean incremental BP reductions than trials conducted between 12 to 24 months, whereas the greatest BP effect was noted in trials lasting <12 months. This is a finding that has been described 10 A similar effect was also seen within individual trials, such as the PREMIER trial, which showed a declining level of BP reduction when participants were examined after 18 months of follow-up compared with the original trial of 6-month follow-up. 21, 22 The most probable explanation for this finding is that of declining adherence to the diet over time, and suggests that participant adherence is of primary importance in any lifestyle intervention program. We also found that larger (n>1000) and medium (n=100-1000) sized trials had less incremental BP effects than smaller trials, possibly reflecting that larger trials tended to be of longer duration with a wider pool of individual risk and motivation, whereas smaller studies may include the most motivated participants. Trials conducted among individuals with hypertension showed significantly greater net BP changes than those conducted in normotensive participants, which may reflect healthier baseline diet and lifestyle practices among nonhypertensive individuals. Other studies have described a beneficial influence of physical activity level on BP reduction, however, in our analysis; there was no incremental BP benefit in trials encouraging physical activity versus those that did not. 10 There was a larger BP effect experienced by individuals who were not already on antihypertensive medications, which may have ramifications as treated individuals make up a large portion of the prevalent hypertensive population. It is important to note, however, that there was still a significant effect appreciated (for both SBP and DBP) in patients currently undergoing pharmacological therapy, and it may be true that dietary modifications would allow for medication withdrawal over time.
We detected an independent association of weight loss with BP reduction. This result was observed irrespective of baseline BMI, which had no correlation with the magnitude of net BP effects. Similar findings have been described in previous analyses and several biologically plausible explanations have been put forward. 12 Weight loss was not, however, associated with net BP reduction among low-sodium or lowsodium, high-potassium diets; a probable reflection of the intricate involvement of these electrolytes in renal BP regulation, which likely has many influences other than weight.
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Strengths and Limitations
Strengths of this study include a rigorous and robust level of clinical evidence by limiting inclusion to only randomized controlled trials, thereby restricting potential confounders. Similarly, 3 comprehensive databases were used to complete literature searches, covering a wide breadth of published studies and ultimately including 24 trials with >23 000 total participants. Furthermore, we limited our inclusion criteria for study duration to trials lasting at least 6 months, which minimizes any over estimation of long-term BP reduction arising from short-term dietary modifications.
There are also some important limitations to point out. We chose to limit the review and analysis to clinical trials completed within the past 25 years; we acknowledge that trials were being conducted on this issue outside of this time frame, but feel that 25 years encompasses a relevant and robust body of evidence and is similar to date ranges used in the evidence review for the 2013 American College of Cardiology/American Heart Association lifestyle management guidelines. 13 In addition, as explained above, there were greater BP reductions among studies of shorter duration and smaller size; not all interventions were equally distributed across the follow-up or sample size spectrum, which allows for the possibility of bias within our dietary subanalysis. For example, although DASH diet interventions exhibited the largest mean net effect size for both SBP and DBP, all the studies included in this category were shortterm (<12 months) trials, which may partially explain the size of the effect. Given our inclusion criteria for study duration, important clinical trials such as the original DASH trial and the OmniHeart trial were excluded from the analysis. However, as noted above, dietary adherence has important implications on BP effect size, and this exclusion requirement limits any over estimation of long-term BP reduction. In addition, the subanalyses were limited by what data were available in published studies; as such, subanalyses based on race, which may interact in important ways with dietary interventions such as sodium reduction, were not possible.
Perspectives
This meta-analysis provides important evidence that dietary interventions offer clinically significant net BP reductions, and that some dietary patterns may be more effective than others. The public health and clinical implications of this research are important, and healthcare providers should consider these when giving dietary recommendations. The DASH intervention that contains many aspects of other approaches (low sodium recommendation and high-potassium, low-fat food groups) may be the most appropriate initial recommendation when BP control is the principle objective, although weight loss and other factors are certainly relevant. This is true for patients who are in the prehypertension range as well as those already taking antihypertensive medications. Importantly, the magnitude of the net effect for the DASH dietary intervention was similar to the effect of drug monotherapies for mild hypertension, providing a possible alternative to medication initiation in early stage hypertension. Adherence to any lifestyle modification is of primary importance and should always be addressed and evaluated. Additional studies are needed to assess the long-term mortality and morbidity effects from BP reduction through dietary intervention.
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What Is New?
• A review of the comparative effectiveness of different dietary approaches to blood pressure (BP) control.
What Is Relevant?
• The DASH (Dietary Approaches to Stop Hypertension) diet was the most effective dietary pattern for blood pressure control, and its magnitude of effect was similar to pharmacological monotherapy.
• The Mediterranean diet that has been shown to reduce the rate of cardiovascular events and mortality, had little effect on BP control.
• Studies of longer duration had a lower net effect, suggesting that dietary adherence declined overtime, though other explanations, such as loss of biological effect cannot be ruled out.
Summary
The results of this meta-analysis of 24 randomized controlled trials showed that dietary modifications have meaningful effects on BP. Some diets are more effective than others, and there are variations in effect based on diet duration and participant demographics that have important clinical and public health implications for hypertension prevention and control.
METHODS
Data Extraction
We retrieved original articles to extract the following study characteristics using a standardized entry database: primary author, date of publication, title, country of origin, sample size, participant demographics, participant health status (i.e. diabetes, coronary artery disease, etc.), use of antihypertensive medication, dietary intervention details, any physical activity details, setting, duration of follow-up for all reported measurements, method of BP ascertainment, effect size, weight loss, and bias assessment. If BP measurements were reported at multiple points in time, data were analyzed for the period of longest follow-up. Some individual studies examined several unique dietary interventions versus a common control; when this was the case, each intervention was considered as a separate comparison against the control group. In cases where incomplete data were presented in the published article, authors were contacted in an effort to obtain the missing information.
Studies were categorized into different dietary pattern interventions based on the approach examined in the trial. Dietary Approaches to Stop Hypertension (DASH) diets followed a protocol involving increased consumption of fruits, vegetables, low-fat dairy, whole grains, lean meats (fish and poultry), nuts and beans, as well as a reduced intake of red meat and fat. Mediterranean diets were characterized by reduced saturated fat in favor of monounsaturated and n-3 fatty acids from nuts, olive oil, and fish, as well as an increased amount of grains, vegetables, and fruits, with decreased levels of red meat. Low sodium diets entailed consuming below 2.3g (100 mmol/day) of total daily sodium. High potassium diets had this as a stated objective of the trial. Low fat diets required that less than 30% of total calories be consumed from fat. Low calorie diets adjusted the daily caloric intake to reduce weight by at least 4.5 kg or 5% of total body weight. When more than one dietary modification was included in the intervention, the study was categorized as reporting on a combined intervention, e.g. as a low sodium, high potassium diet.
Bias Assessment
The presence of publication bias was assessed via creation and visual inspection of funnel plots, by plotting SEs against the effect size for each study. The Egger test was used to quantify any asymmetry among the funnel plots, and the trim-and-fill method was utilized to adjust for any omissions and potential bias. A Cochrane Risk of Bias tool was used to evaluate any potential methodological concerns amongst included studies. Each trial was assessed for: selection bias (random sequence allocation and allocation concealment), performance bias (blinding participants and personnel), detection bias (blinding outcome assessors), attrition bias (incomplete outcome data), and reporting bias (selective reporting). Each trial was classified as low, high, or unclear on the risk of bias scale.
RESULTS
Bias Assessment
Funnel plots ( Figure S3 ) of SE versus effect size for each study demonstrate that the distribution of effect size estimates for individual comparison groups was approximately symmetrical around the pooled estimate; however, potential missing studies were visually noted in the region of small sample size and low to negative effect for both SBP and DBP. Further assessment was completed via the Egger test, which did not identify any asymmetry in either SBP (P = 0.48) or DBP (P = 0.45) plots. Sensitivity analysis was completed utilizing the trimand-fill method which did not identify any missing studies or change the effect size. Taken together, this suggests there is a low likelihood of publication bias influencing the results observed. Potential methodologic biases are detailed in Figure S4 . Studies mostly generated a low risk of bias, though in a small number of studies a comprehensive bias assessment revealed a number of unclear risk components. 
